{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:33:38Z","timestamp":1791290018803,"version":"4.3.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.bcp.2008.04.014","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T07:13:12Z","timestamp":1209885192000},"page":"249-257","source":"Crossref","is-referenced-by-count":48,"title":["In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway"],"prefix":"10.1016","volume":"76","author":[{"given":"Oranun","family":"Kerdpin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Knights","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Elliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.bcp.2008.04.014_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00003495-199100413-00004","article-title":"Clinical pharmacology of loop diuretics","volume":"41","author":"Brater","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2008.04.014_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","article-title":"Furosemide (frusemide)\u2014A pharmacokinetic\/pharmacodynamic review (part I)","volume":"18","author":"Boles Ponto","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bcp.2008.04.014_bib3","first-page":"337","article-title":"Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay","volume":"8","author":"Smith","year":"1980","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01059086","article-title":"Frusemide pharmacokinetics and pharmacodynamics in health and disease \u2013 An update","volume":"17","author":"Hammarlund-Udenaes","year":"1989","journal-title":"J Pharmacokinet Biopharmceut"},{"key":"10.1016\/j.bcp.2008.04.014_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1681\/ASN.V72345","article-title":"Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid","volume":"7","author":"Pichette","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2008.04.014_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/BF00607088","article-title":"Biotransformation of furosemide in kidney transplant patients","volume":"24","author":"Smith","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpt197722170","article-title":"Elimination of furosemide in healthy subjects and in those with renal failure","volume":"22","author":"Beermann","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2008.04.014_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2008.04.014_bib9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.bcp.2008.04.014_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: metabolism, expression, and disease","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2008.04.014_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1124\/jpet.107.128603","article-title":"Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation","volume":"323","author":"Gaganis","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.04.014_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-2952(93)90064-4","article-title":"The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs","volume":"45","author":"Sutherland","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0006-2952(97)00534-0","article-title":"Drug glucuronidation by human renal UDP-glucuronosyltransferases","volume":"55","author":"McGurk","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002280050074","article-title":"Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney","volume":"50","author":"Raoof","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2125.2005.02393.x","article-title":"Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain","volume":"60","author":"Hiraoka","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib16","first-page":"121","article-title":"Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney","volume":"29","author":"Soars","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.0306-5251.2001.01487.x","article-title":"The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes","volume":"52","author":"Bowalgaha","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.301.1.382","article-title":"In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance","volume":"301","author":"Soars","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.04.014_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bcp.2003.08.025","article-title":"Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7","volume":"67","author":"Tsoutsikos","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib20","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.bcp.2007.01.030","article-title":"Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransfearse (UGT) 1A9 and 2B7","volume":"73","author":"Gaganis","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","article-title":"S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen","volume":"60","author":"Bowalgaha","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In vitro\u2013in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine","volume":"54","author":"Boase","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/dmd.31.9.1086","article-title":"Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7","volume":"31","author":"Stone","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine\u2013valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/dmd.105.007369","article-title":"Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) \u201cprobes\u201d for human UDP-glucuronosyltransferases","volume":"34","author":"Uchaipichat","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib28","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1124\/dmd.106.012385","article-title":"Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9","volume":"34","author":"Kerdpin","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib29","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/dmd.31.9.1125","article-title":"Evaluation of 3\u2019-azido-3\u2019-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism","volume":"31","author":"Court","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.abb.2006.07.010","article-title":"Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone","volume":"454","author":"Nishiyama","year":"2006","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bcp.2008.04.014_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro\u2013in vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.04.014_bib32","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u2018albumin effect\u2019 and drug glucuronidation: bovine serum albumin and fatty acid free human serum albumin enhance the glucuronidation of UGT1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib33","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1021\/ci600248e","article-title":"The importance of local chemical structure for chemical metabolism by human uridine 5\u2019-diphosphate \u2013 glucuronosyltransferase","volume":"46","author":"Sorich","year":"2006","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bcp.2008.04.014_bib34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0090-9556(24)15041-6","article-title":"Studies of the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10","volume":"27","author":"Cheng","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0076-6879(05)00007-8","article-title":"Isoform selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases","volume":"400","author":"Court","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.bcp.2008.04.014_bib36","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In vitro\u2013in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2008.04.014_bib37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0300-483X(02)00449-3","article-title":"Toxicological significance of genetic polymorphisms of UDP-glucuronosyltransferase","volume":"181\u2013182","author":"Miners","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.bcp.2008.04.014_bib38","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/FPC.0b013e328256b1b6","article-title":"Influence of mutations associated with Gilbert and Crigler\u2013Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A (UGT1A) substrates","volume":"17","author":"Udomuksorn","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.bcp.2008.04.014_bib39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00008571-200011000-00002","article-title":"Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance","volume":"10","author":"Bhasker","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.bcp.2008.04.014_bib40","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/dmd.106.009787","article-title":"The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver","volume":"34","author":"Girard","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2008.04.014_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/jpet.103.054072","article-title":"Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs","volume":"307","author":"Villeneuve","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.04.014_bib42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/clpt.1987.75","article-title":"Inhibition of renal clearance of furosemide by pentopril, an angiotensin converting enzyme inhibitor","volume":"41","author":"Rakhit","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2008.04.014_bib43","first-page":"177","article-title":"Clearance of furosemide by the gastrointestinal tract","volume":"236","author":"Valentine","year":"1986","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295208002931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295208002931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T01:32:27Z","timestamp":1738200747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295208002931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0006295208002931"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2008.04.014","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}